Want to see PBYI full AI Analyst Report?
PBYI Stock Chart & Stats
$9.24
$0.15(1.88%)
At close: 4:00 PM EDT
$9.24
$0.15(1.88%)
Day’s Range― - ―
52-Week Range$4.58 - $10.10
Previous CloseN/A
Volume23.96K
Average Volume (3M)296.08K
Market Cap
$507.94M
Enterprise Value$337.47
Total Cash (Recent Filing)$93.90M
Total Debt (Recent Filing)$4.82M
Price to Earnings (P/E)17.7
Beta1.06
Next Earnings
Oct 29, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.54
Shares Outstanding51,620,068
10 Day Avg. Volume318,255
30 Day Avg. Volume296,083
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.28
Price to Sales (P/S)1.30
P/FCF Ratio7.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$6.00Price Target Upside-35.06% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.38
Revenue Forecast (FY)$226.00M
Bulls Say, Bears Say
Bulls Say
NERLYNX Commercial GrowthRising NERLYNX demand and higher full-year guidance indicate improving commercial execution around Puma’s primary marketed therapy. If sustained, stronger product revenue can support profitability, fund clinical development, and reinforce the company’s oncology market position over the next several quarters.
Debt-free Balance SheetEliminating debt materially improves financial flexibility by removing principal obligations and interest-related pressure. The cash and securities balance gives Puma greater capacity to support commercialization and clinical programs while providing a stronger buffer if operating cash generation becomes uneven.
Expanding Oncology PipelineInitiating ALISCA-Lung2 broadens Puma’s development pipeline beyond its current breast-cancer product and creates a potential route to additional oncology indications. The trial’s biomarker work may also help define responsive patients and improve future development decisions if efficacy signals emerge.
Bears Say
High Gross-to-net DeductionsElevated gross-to-net deductions reduce the revenue Puma ultimately retains from NERLYNX prescriptions, limiting the benefit of gross demand growth. Continued Medicaid mix pressure or other rebates and allowances could weigh on sustainable net sales and constrain margins across future periods.
China Royalty Reduction RiskA generics-triggered reduction in China sublicense royalties could lower a recurring economic contribution from the company’s international rights. Because the potential change is tied to generic market share, it represents a structural medium-term risk to revenue quality and earnings support.
Rising R&D Cash DemandsHigher clinical investment can advance Puma’s pipeline, but rapidly rising R&D and cash burn reduce the near-term conversion of commercial revenue into liquidity. Sustained spending growth could pressure cash generation and require tighter prioritization across development programs despite the debt-free balance sheet.
Puma Biotechnology News
PBYI FAQ
What was Puma Biotechnology’s price range in the past 12 months?
Puma Biotechnology lowest stock price was $4.58 and its highest was $10.10 in the past 12 months.
What is Puma Biotechnology’s market cap?
Puma Biotechnology’s market cap is $507.94M.
When is Puma Biotechnology’s upcoming earnings report date?
Puma Biotechnology’s upcoming earnings report date is Oct 29, 2026 which is in 26 days.
How were Puma Biotechnology’s earnings last quarter?
Puma Biotechnology released its earnings results on Aug 06, 2026. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.12.
Is Puma Biotechnology overvalued?
According to Wall Street analysts Puma Biotechnology’s price is currently Overvalued.
Does Puma Biotechnology pay dividends?
Puma Biotechnology does not currently pay dividends.
What is Puma Biotechnology’s EPS estimate?
Puma Biotechnology’s EPS estimate is 0.09.
How many shares outstanding does Puma Biotechnology have?
Puma Biotechnology has 51,620,068 shares outstanding.
What happened to Puma Biotechnology’s price movement after its last earnings report?
Puma Biotechnology reported an EPS of $0.16 in its last earnings report, beating expectations of $0.04. Following the earnings report the stock price went up 9.729%.
Which hedge fund is a major shareholder of Puma Biotechnology?
Currently, no hedge funds are holding shares in PBYI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Puma Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6.00 (-35.06% Downside)
$6.00 (-35.06% Downside)
Blogger Sentiment
Neutral
PBYI Sentiment 50%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 16.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 12.9%
Last 30 Days ▲ 12.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.12%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
PBYI Company Deck
PBYI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights strong commercial momentum: meaningful QoQ and YoY increases in NERLYNX demand and bottle sales, a return to GAAP profitability in Q2, raised full-year revenue and net income guidance, and elimination of debt. These positives are tempered by pressure from high gross-to-net deductions (~28%), potential royalty reductions in China when generics gain share, rising R&D spend and increased quarter-over-quarter cash burn, and operational items like elevated DSO and a QoQ decline in new patient starts. On balance, the company appears to be in a strengthening commercial and financial position while managing identifiable near-term risks tied to deductions, international royalties, and increased investment in clinical programs.View all PBYI earnings summariesPBYI Stock 12 Month Forecast
Average Price Target
$6.00
▼(-35.06% Downside)
Technical Analysis
Heron Therapeutics
―
Voyager Therapeutics
―
Foghorn Therapeutics
―
Vor Biopharma
―
Tenaya Therapeutics
―
Ownership Overview
15.83% Insiders
15.42% Mutual Funds
18.64% Other Institutional Investors
32.85% Public Companies and
Individual Investors